Raisch Dennis W, Fudala Paul J, Saxon Andrew J, Walsh Robert, Casadonte Paul, Ling Walter, Johnson Bankole A, Malkerneker Usha, Ordorica Patricia, Williford William O, Sather Mike R
Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA.
J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):23-32. doi: 10.1331/1544345052843200.
To assess the perceptions and attitudes of pharmacists and pharmacy technicians involved in an office-based opioid dependence treatment program using buprenorphine/naloxone.
Cross-sectional attitudinal assessment.
Community, outpatient hospital, and clinic pharmacies.
Pharmacists and technicians participating in a clinical trial of opioid dependence treatment using buprenorphine/naloxone.
Written and telephone surveys followed by interviews with open-ended items.
Attitudes and perceptions regarding opioid-dependent patients and use of buprenorphine/naloxone for treatment of opioid dependence.
Pharmacies in seven states (New York, Virginia, Illinois, Florida, Texas, California, and Washington) participated in the clinical trial. A total of 40 pharmacists and pharmacy technicians responded to the initial written survey, representing 27 of the 32 pharmacies (84%). Follow-up interviews were obtained from one individual at 30 of those pharmacies (93.8%). Most pharmacy personnel (77.5%) involved with this study were not more concerned about theft or break-ins and would be willing to participate in opioid dependence treatment as the medication became available commercially (70%). The majority of respondents (85%) indicated that patients did not cause problems at their pharmacies. Compared with their experiences in administering other narcotic medications, most respondents did not express increased concern regarding prescription forgery (75%) or diversion (80%) of buprenorphine/naloxone.
The majority of respondents expressed positive attitudes and perceptions regarding patients treated for opioid dependence with buprenorphine/naloxone.
评估参与使用丁丙诺啡/纳洛酮的门诊阿片类药物依赖治疗项目的药剂师和药房技术员的看法与态度。
横断面态度评估。
社区药房、门诊医院药房和诊所药房。
参与使用丁丙诺啡/纳洛酮进行阿片类药物依赖治疗临床试验的药剂师和技术员。
书面和电话调查,随后进行开放式问题访谈。
对阿片类药物依赖患者的态度和看法,以及使用丁丙诺啡/纳洛酮治疗阿片类药物依赖的情况。
七个州(纽约州、弗吉尼亚州、伊利诺伊州、佛罗里达州、得克萨斯州、加利福尼亚州和华盛顿州)的药房参与了该临床试验。共有40名药剂师和药房技术员回复了初始书面调查,占32家药房中的27家(84%)。对其中30家药房(93.8%)的一名人员进行了后续访谈。参与本研究的大多数药房工作人员(77.5%)并不更担心盗窃或入室盗窃,并且随着该药物上市销售,愿意参与阿片类药物依赖治疗(70%)。大多数受访者(85%)表示患者在他们的药房没有引发问题。与他们管理其他麻醉药品的经历相比,大多数受访者对丁丙诺啡/纳洛酮的处方伪造(75%)或转移(80%)没有表现出更多担忧。
大多数受访者对使用丁丙诺啡/纳洛酮治疗阿片类药物依赖的患者表达了积极的态度和看法。